CutoSense

Based in Turku, Finland, CutoSense is a medical technology company established in 2016 as a spin-off from extensive academic research. The company is focused on developing advanced systems for the assessment and treatment of difficult-to-heal wounds. CutoSense has secured funding across two seed rounds in 2017 and 2018 from investors including EBD Group, Life Science Accelerator, New Factory, CHMG Capital, and Aalto University.

The core of CutoSense's offering is the WoundWatch®, a system currently in the prototype stage designed for both monitoring and treating chronic and surgical wounds. This system comprises a perforated, electrode-containing substrate placed on the wound beneath the primary dressing, a measurement and treatment unit connected to the substrate, and analytical software. This setup enables healthcare professionals to assess the wound's status through bioimpedance measurements without removing the dressing, which reduces mechanical stress on new tissue and minimizes patient discomfort. The technology also incorporates electro-stimulation to promote faster healing.

The company's business model is B2B2P, targeting healthcare institutions, clinics, and wound care specialists. By providing a more detailed and less invasive method for wound management, CutoSense aims to improve patient quality of life and assist healthcare providers in delivering more effective treatments. The company actively collaborates with universities and healthcare professionals to refine its technology. CutoSense has also strengthened its intellectual property portfolio, securing multiple US patents for its wound dressing design and treatment methods in 2019.

Keywords: wound care, medical devices, bioimpedance, electro-stimulation, chronic wounds, wound monitoring, HealthTech, diagnostic equipment, therapeutic devices, wound assessment, medical technology, wound treatment systems, hard-to-heal wounds, smart dressing, tissue monitoring, clinical decision support, non-invasive monitoring, Turku, Finland